At mid-afternoon, we’ve seen some changes among today’s big movers. On the plus side are Medivation Inc. (NASDAQ: MDVN, Live Deal Inc. (NASDAQ: LIVE, RadiSys Corp. (NASDAQ: RSYS), Savient Pharmaceuticals Inc. (NASDAQ: SVNT), and Vringo Inc. (NASDAQ: VRNG).
Medivation has jumped nearly 25% to $69.12 after posting a new 52-week high of $70.87 earlier today. The development stage drug maker has reported highly positive results on a test of its late-stage prostate cancer treatment. We have more coverage here.
Live Deal is up nearly 25% at $5.47. The customer acquisition company got a capital infusion on Monday from the private equity division of Isaac Organization.
RadiSys is up nearly 22% at $7.35 in a 52-week range of $4.01-$9.38. The company has announced a ruggedized version of a Core processor from Intel Corp. (NASDAQ: INTC).
Savient is down more than 12% at $2.22. The drug company lost its CEO, who has joined Dendreon Corp. (NASDAQ: DNDN) as its new CEO.
Vringo is down nearly -6% at $1.32. The social media company is giving back some of the 30% gain it enjoyed yesterday.
The DJIA is up 1% at around 12,760, the S&P 500 is up 1.19% at about 1,328, and the Nasdaq Composite is up 1.33% at about 2,851.
Paul Ausick
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
